Agena Bioscience has introduced the VeriDose pharmacogenomics (PGx) research-use-only panel that can detect CYP2D6 copy number variation (CNV) in the presence of the CYP2D6/CYP2D7 hybrid alleles.
Up to 37% of people have CYP2D6/CYP2D7 hybrid alleles, which the company noted are not detected with most PGx tests, creating a risk for inaccurate results about drug metabolism. Testing for copy number may be done in parallel with the company's genotyping products in the same workflow, Agena said.
